Affimed N.V. (AFMD) News, Price and Chart - FAWS

Your browser has either disabled or does not support javascript. Javascript is required for full website experience.

Tue May 18th, 2021

- 13:00
  AnalysisImmutep - Relatively Unknown Pure Play On LAG3 Surrounded By Major Pharma; Positioned Well For Large Biobucks Deal Or TakeoutSeeking Alpha

Fri May 14th, 2021

- 10:26
  AnalysisCould Affimed Be a Millionaire-Maker Stock?The Motley Fool

Tue April 20th, 2021

- 00:29
  AnalysisAffimed's Novel Immune Engineering Approach In OncologySeeking Alpha

Sun April 18th, 2021

- 19:25
  AnalysisAffimed: Wholly-Owned Pipeline Programs Support A Long-Term InvestmentSeeking Alpha

Thu April 15th, 2021

- 21:18
  AnalysisWhy Affimed N.V. Stock Dropped TodayThe Motley Fool
- 19:31
  EarningsAnalysisAffimed N.V. (AFMD) CEO Adi Hoess on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha

Wed March 10th, 2021

- 18:50
  ^{0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9}
  AnalysisWhy Affimed N.V. Stock Is Soaring TodayThe Motley Fool

Sat December 19th, 2020

- 13:40
  ^{0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9}
  AnalysisAffimed's Stockpile Of Partnerships Supports A Long-Term InvestmentSeeking Alpha

Tue November 10th, 2020

- 19:46
  ^{0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9
  0
  1
  2
  3
  4
  5
  6
  7
  8
  9}
  EarningsAnalysisAffimed N.V. (AFMD) CEO Adi Hoess on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha
- 19:30
  EarningsAnalysisAffimed N.V. (AFMD) Q3 2020 Earnings Call TranscriptThe Motley Fool
- 15:20
  EarningsAnalysisAffimed N.V.'s (AFMD) CEO Adi Hoess On Q3 2020 Results - Quick Version Earnings Call TranscriptSeeking Alpha

Thu October 22nd, 2020

- 11:26
  AnalysisOraSure's Emergency Use Authorization, And Other News: The Good, Bad And Ugly Of BiopharmaSeeking Alpha

Tue August 11th, 2020

- 15:41
  EarningsAnalysisAffimed N.V. (AFMD) CEO Adi Hoess on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha

Fri July 24th, 2020

- 15:12
  AnalysisAffimed's Innate Immune Programs Offer A Compelling Value At Current Price LevelsSeeking Alpha

Wed July 1st, 2020

- 16:58
  AnalysisAffimed: Updates To Thesis, Time To Gain Exposure To Innate Immuno-OncologySeeking Alpha

Tue June 23rd, 2020

- 20:30
  EarningsAnalysisAffimed N.V. (AFMD) Q1 2020 Earnings Call TranscriptThe Motley Fool
- 14:50
  EarningsAnalysisAffimed N.V. (AFMD) CEO Adi Hoess on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha + 1 more

SPY$395.63-6.2%

QQQ$315.85-8.5%

DOW$64.140.94%

--

SPY$395.63-6.2%

QQQ$315.85-8.5%

DOW$64.140.94%

--

About Developer Contact